GLADYS KIMELI: Open Payments
NPI 1356823496 · SAGINAW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,958 in 241 payments from 18 companies in 2025. Trend: 2023 $3,805 · 2024 $5,491 · 2025 $3,958
Food & beverage: $3,958
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 42 | $646 |
| Alkermes, Inc. | 18 | $424 |
| Neurocrine BioSciences, Inc. | 24 | $384 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $373 |
| Vanda Pharmaceuticals Inc. | 23 | $346 |
| Janssen Pharmaceuticals, Inc | 14 | $297 |
| Lundbeck LLC | 12 | $256 |
| Collegium Pharmaceutical, Inc. | 18 | $211 |
| Axsome Therapeutics, Inc. | 8 | $172 |
| E.R. Squibb & Sons, L.L.C. | 18 | $161 |
Products named: REXULTI, ARISTADA, INGREZZA, CAPLYTA, FANAPT, ABILIFY ASIMTUFII, Jornay PM, Auvelity.
Industry payments across MI — which companies pay providers there.
